Literature DB >> 23277020

Assessment criteria for compensation of occupational bladder cancer.

Wolfgang Schops1, Olaf Jungmann, Jurgen Zumbe, Michael Zellner, Jan G Hengstler, Klaus Golka.   

Abstract

In Germany, more than 100 bladder tumor cases are annually recognized as occupational disease and compensated, given that medical experts regard exposure to carcinogenic aromatic amines as a likely cause of cancer. The amount of compensation is initially based on the tumor staging and grading at the time of initial diagnosis ("basic MdE") (MdE--reduction of earning capacity) and is adapted after a recurrence-free period of 2 and 5 years, respectively. In the event of treatment or tumor-related secondary conditions, the monthly compensation increases based on the severity of the objectified functional disorder. In the following article, medical experts specializing in this field provide a complete list of all known disorders, including treatment-related loss of a kidney or erectile dysfunction. In addition, the weighting of medical criteria in the assessment and calculation of the compensation is analyzed in greater detail. Since the given criteria are based on comprehensible experiences of urologists with their patients, they also provide medical experts in other countries with valuable points of reference for the calculation of the compensation.

Entities:  

Mesh:

Year:  2013        PMID: 23277020     DOI: 10.2741/e646

Source DB:  PubMed          Journal:  Front Biosci (Elite Ed)        ISSN: 1945-0494


  2 in total

Review 1.  [Prerequisites for a convincing (neuro-)urology opinion : Importance of objectivity in the legal sense of full proof, occurring under duty of compliance of the surveyed person].

Authors:  M Zellner; W Schöps; O P Jungmann; R Böthig; T Kadhum; K Golka
Journal:  Urologe A       Date:  2018-07       Impact factor: 0.639

Review 2.  Medical follow-up for workers exposed to bladder carcinogens: the French evidence-based and pragmatic statement.

Authors:  Bénédicte Clin; Jean-Claude Pairon
Journal:  BMC Public Health       Date:  2014-11-06       Impact factor: 3.295

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.